Company: IONQ
Filing Date: 2025-07-07
Form Type: 424B5
Source: 0001193125-25-155901
Chunk: 57

Company: IonQ, Inc.
Filing Date: 2025-07-07
Form: 424B5
Chunk 57
---
 Agreement and Plan of Merger (the “Merger Agreement”), with dMY and Ion Trap
Acquisition Inc., a direct, wholly owned subsidiary of dMY (the “Merger Sub”). Pursuant to the Merger Agreement, on September 30, 2021, the Merger Sub was merged with and into Legacy

1

IonQ with Legacy IonQ continuing as the surviving corporation following the merger, becoming a wholly owned subsidiary of dMY, and the separate corporate existence of the Merger Sub ceased (the
“Business Combination”). Following the closing of the Business Combination, dMY changed its name to IonQ, Inc., and Legacy IonQ changed its name to IonQ Quantum, Inc.

Our principal executive offices are located at 4505 Campus Drive, College Park, MD 20740, and our telephone number is (301) 298-7997. Our corporate website address is https://ionq.com. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus
is an inactive textual reference only.

The Securities That May Be Offered

We may offer or sell common stock, preferred stock, depositary shares, debt securities, warrants, subscription rights, purchase contracts and
units in one or more offerings and in any combination, and the selling stockholders to be named in a supplement to this prospectus may from time to time offer and sell shares of our common stock. Each time securities are offered with this
prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and terms of the securities being offered and the net proceeds we expect to receive from that sale. We will not receive any proceeds from the sale of
our common stock by the selling stockholders.

The securities may be sold to or through underwriters, dealers or agents or directly to
purchasers or as otherwise set forth in the section titled “Plan of Distribution.” Each prospectus supplement will set forth the names of any underwriters, dealers, agents or other entities involved in the sale of securities described in
that prospectus supplement and any applicable fee, commission or discount arrangements with them.

Common Stock

We or the selling stockholders may offer shares of our common stock, par value $0.0001 per share, either alone or underlying other registered
securities convertible into our common stock. Holders of our common stock are entitled to receive dividends declared by our board of directors out of funds legally available